Barclays initiates coverage of Inspire Medical with underweight rating and $65 target price
INSP•Barclays initiated coverage of Inspire Medical with an underweight rating and a $65 target price.
Related News
Jardine Matheson chief people officer Raymond Co buys shares worth US$115,046
JMHLY•
Vertical Aerospace files US patent infringement counterclaim against Archer over Midnight eVTOL
EVTL•
Canadian National Railway Co: Citigroup cuts target price to $143 from $151
CNI•
Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy
LPCN•
Federal Reserve events diary
TLT•